RVPH vs. MIST, CNTB, ALLK, GNLX, DMAC, MCRB, ORMP, BRNS, ACRS, and CLSD
Should you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Milestone Pharmaceuticals (MIST), Connect Biopharma (CNTB), Allakos (ALLK), Genelux (GNLX), DiaMedica Therapeutics (DMAC), Seres Therapeutics (MCRB), Oramed Pharmaceuticals (ORMP), Barinthus Biotherapeutics (BRNS), Aclaris Therapeutics (ACRS), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry.
Milestone Pharmaceuticals (NASDAQ:MIST) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
Reviva Pharmaceuticals' return on equity of -170.99% beat Milestone Pharmaceuticals' return on equity.
Milestone Pharmaceuticals currently has a consensus target price of $10.75, suggesting a potential upside of 543.71%. Reviva Pharmaceuticals has a consensus target price of $16.75, suggesting a potential upside of 454.64%. Given Reviva Pharmaceuticals' higher probable upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Reviva Pharmaceuticals.
86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 10.4% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 31.8% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Reviva Pharmaceuticals had 11 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 11 mentions for Reviva Pharmaceuticals and 0 mentions for Milestone Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.69 beat Milestone Pharmaceuticals' score of 0.60 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.
Reviva Pharmaceuticals has lower revenue, but higher earnings than Milestone Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Milestone Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.
Milestone Pharmaceuticals received 59 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.89% of users gave Reviva Pharmaceuticals an outperform vote while only 67.57% of users gave Milestone Pharmaceuticals an outperform vote.
Summary
Milestone Pharmaceuticals beats Reviva Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Reviva Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reviva Pharmaceuticals Competitors List
Related Companies and Tools
